Patents/Assignees

CRISPR THERAPEUTICS AG

34 patents in portfolio

US11851653utility2023
Materials and Methods for Treatment of Alpha-1 Antitrypsin Deficiency
0 cites
US11833225utility2023
Methods and Compositions for Efficient Gene Deletion
0 cites
US11827877utility2023
Compositions and Methods for Genomic Editing by Insertion of Donor Polynucleotides
0 cites
US11795238utility2023
Anti-idiotype Antibodies Targeting Anti-cd70 Chimeric Antigen Receptor
0 cites
US11679130utility2023
Genetically Engineered T Cells with Regnase-1 And/or TGFBRII Disruption Have Improved Functionality and Persistence
0 cites
US11679131utility2023
Genetically Engineered T Cells with Regnase-1 And/or TGFBRII Disruption Have Improved Functionality and Persistence
0 cites
US11649438utility2023
Methods and Compositions for Treating Cancer
0 cites
US11622977utility2023
Materials and Methods for Engineering Cells and Uses Thereof in Immuno-oncology
0 cites
US11591381utility2023
Gene-edited Natural Killer Cells
0 cites
US11578309utility2023
Universal Donor Cells
0 cites
US11578323utility2023
Rna-programmable Endonuclease Systems and Their Use in Genome Editing and Other Applications
0 cites
US11564997utility2023
Materials and Methods for Treatment of Friedreich Ataxia and Other Related Disorders
0 cites
US11566230utility2023
Universal Donor Cells
0 cites
US11559588utility2023
Materials and Methods for Treatment of Spinocerebellar Ataxia Type 1 (SCA1) and Other Spinocerebellar Ataxia Type 1 Protein (ATXN1) Gene Related Conditions or Disorders
0 cites

← PreviousPage 2 of 2